These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 12494060)
41. [Clinical trials on protective efficacy of antihypertensive agents for organ damage due to diabetes mellitus complicated with hypertension]. Higashiura K Nihon Rinsho; 2004 Mar; 62 Suppl 3():623-7. PubMed ID: 15171446 [No Abstract] [Full Text] [Related]
42. [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV Kardiologiia; 2003; 43(2):88-95. PubMed ID: 12891278 [TBL] [Abstract][Full Text] [Related]
43. Irbesartan treatment in hypertension. Brown MJ Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301 [TBL] [Abstract][Full Text] [Related]
44. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Devereux RB; Lyle PA Expert Opin Pharmacother; 2004 Nov; 5(11):2311-20. PubMed ID: 15500378 [TBL] [Abstract][Full Text] [Related]
45. [What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension]. Eguchi K; Kario K; Shimada K Nihon Rinsho; 2002 Sep; 60 Suppl 9():679-84. PubMed ID: 12387069 [No Abstract] [Full Text] [Related]
46. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H; Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960 [TBL] [Abstract][Full Text] [Related]
47. [Treatment of hypertension in the elderly]. Hohage H; Gerhardt U; Suwelack BM Med Klin (Munich); 2003 Sep; 98(9):511-21. PubMed ID: 14551708 [No Abstract] [Full Text] [Related]
48. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745 [TBL] [Abstract][Full Text] [Related]
50. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Krauser DG; Devereux RB Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470 [TBL] [Abstract][Full Text] [Related]
51. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047 [TBL] [Abstract][Full Text] [Related]
52. [Recent intervention studies with antihypertensive drugs and their influence on guidelines]. Rahn KH Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679 [TBL] [Abstract][Full Text] [Related]
53. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ]. Tschöpe C; Tschöpe R; Unger T MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162 [No Abstract] [Full Text] [Related]
54. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. Malmqvist K; Kahan T; Edner M; Bergfeldt L J Hum Hypertens; 2007 Dec; 21(12):956-65. PubMed ID: 17637792 [TBL] [Abstract][Full Text] [Related]
55. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416 [TBL] [Abstract][Full Text] [Related]
56. [Efficacy of a converting enzyme inhibitor in the prevention of recurrence of stroke]. Masson C Presse Med; 2001 Nov; 30(35):1716-7. PubMed ID: 11775593 [No Abstract] [Full Text] [Related]
57. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226 [TBL] [Abstract][Full Text] [Related]